Helping The Neediest Patients: Stopping Insurers’ Rejection Of Prescription Medications

That’s the question a controversial Boston-based non-profit, the Institute for Clinical and Economic Review (ICER), convened about last week in St. Louis to discuss. The group, who notoriously “cherry-picks data,” often reviews new medications, deems them too expensive, and allows the insurance industry justify limiting coverage for new treatments and pass costs directly onto patients.